BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 16321607)

  • 21. alpha,alpha'-trehalose 6,6'-dibehenate in non-phospholipid-based liposomes enables direct interaction with trehalose, offering stability during freeze-drying.
    Christensen D; Kirby D; Foged C; Agger EM; Andersen P; Perrie Y; Nielsen HM
    Biochim Biophys Acta; 2008 May; 1778(5):1365-73. PubMed ID: 18261458
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Mincle-activating adjuvant TDB induces MyD88-dependent Th1 and Th17 responses through IL-1R signaling.
    Desel C; Werninghaus K; Ritter M; Jozefowski K; Wenzel J; Russkamp N; Schleicher U; Christensen D; Wirtz S; Kirschning C; Agger EM; Prazeres da Costa C; Lang R
    PLoS One; 2013; 8(1):e53531. PubMed ID: 23308247
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the depot effect and immunogenicity of liposomes based on dimethyldioctadecylammonium (DDA), 3β-[N-(N',N'-Dimethylaminoethane)carbomyl] cholesterol (DC-Chol), and 1,2-Dioleoyl-3-trimethylammonium propane (DOTAP): prolonged liposome retention mediates stronger Th1 responses.
    Henriksen-Lacey M; Christensen D; Bramwell VW; Lindenstrøm T; Agger EM; Andersen P; Perrie Y
    Mol Pharm; 2011 Feb; 8(1):153-61. PubMed ID: 21117621
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased potential of a cationic liposome-based delivery system: enhancing stability and sustained immunological activity in pre-clinical development.
    Mohammed AR; Bramwell VW; Kirby DJ; McNeil SE; Perrie Y
    Eur J Pharm Biopharm; 2010 Nov; 76(3):404-12. PubMed ID: 20884349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Manipulation of the surface pegylation in combination with reduced vesicle size of cationic liposomal adjuvants modifies their clearance kinetics from the injection site, and the rate and type of T cell response.
    Kaur R; Bramwell VW; Kirby DJ; Perrie Y
    J Control Release; 2012 Dec; 164(3):331-7. PubMed ID: 22800572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Designing CAF-adjuvanted dry powder vaccines: spray drying preserves the adjuvant activity of CAF01.
    Ingvarsson PT; Schmidt ST; Christensen D; Larsen NB; Hinrichs WL; Andersen P; Rantanen J; Nielsen HM; Yang M; Foged C
    J Control Release; 2013 May; 167(3):256-64. PubMed ID: 23415813
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elucidating the mechanisms of protein antigen adsorption to the CAF/NAF liposomal vaccine adjuvant systems: effect of charge, fluidity and antigen-to-lipid ratio.
    Hamborg M; Rose F; Jorgensen L; Bjorklund K; Pedersen HB; Christensen D; Foged C
    Biochim Biophys Acta; 2014 Aug; 1838(8):2001-10. PubMed ID: 24769435
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity and protective efficacy of DMT liposome-adjuvanted tuberculosis subunit CTT3H vaccine.
    Teng X; Tian M; Li J; Tan S; Yuan X; Yu Q; Jing Y; Zhang Z; Yue T; Zhou L; Fan X
    Hum Vaccin Immunother; 2015; 11(6):1456-64. PubMed ID: 25905680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chlamydia muridarum T-cell antigens formulated with the adjuvant DDA/TDB induce immunity against infection that correlates with a high frequency of gamma interferon (IFN-gamma)/tumor necrosis factor alpha and IFN-gamma/interleukin-17 double-positive CD4+ T cells.
    Yu H; Jiang X; Shen C; Karunakaran KP; Jiang J; Rosin NL; Brunham RC
    Infect Immun; 2010 May; 78(5):2272-82. PubMed ID: 20231405
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protein antigen adsorption to the DDA/TDB liposomal adjuvant: effect on protein structure, stability, and liposome physicochemical characteristics.
    Hamborg M; Jorgensen L; Bojsen AR; Christensen D; Foged C
    Pharm Res; 2013 Jan; 30(1):140-55. PubMed ID: 22956169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Small cationic DDA:TDB liposomes as protein vaccine adjuvants obviate the need for TLR agonists in inducing cellular and humoral responses.
    Milicic A; Kaur R; Reyes-Sandoval A; Tang CK; Honeycutt J; Perrie Y; Hill AV
    PLoS One; 2012; 7(3):e34255. PubMed ID: 22470545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toll like-receptor agonist Pam
    Kennerknecht K; Noschka R; Löffler F; Wehrstedt S; Pedersen GK; Mayer D; Grieshober M; Christensen D; Stenger S
    Med Microbiol Immunol; 2020 Apr; 209(2):163-176. PubMed ID: 32020284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incorporation of the TLR4 agonist monophosphoryl lipid A into the bilayer of DDA/TDB liposomes: physico-chemical characterization and induction of CD8+ T-cell responses in vivo.
    Nordly P; Agger EM; Andersen P; Nielsen HM; Foged C
    Pharm Res; 2011 Mar; 28(3):553-62. PubMed ID: 21042837
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunocorrelates of CAF family adjuvants.
    Pedersen GK; Andersen P; Christensen D
    Semin Immunol; 2018 Oct; 39():4-13. PubMed ID: 30396811
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nano-Self-Assemblies Based on Synthetic Analogues of Mycobacterial Monomycoloyl Glycerol and DDA: Supramolecular Structure and Adjuvant Efficacy.
    Martin-Bertelsen B; Korsholm KS; Roces CB; Nielsen MH; Christensen D; Franzyk H; Yaghmur A; Foged C
    Mol Pharm; 2016 Aug; 13(8):2771-81. PubMed ID: 27377146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. APC targeting enhances immunogenicity of a novel multistage Fc-fusion tuberculosis vaccine in mice.
    Soleimanpour S; Farsiani H; Mosavat A; Ghazvini K; Eydgahi MR; Sankian M; Sadeghian H; Meshkat Z; Rezaee SA
    Appl Microbiol Biotechnol; 2015 Dec; 99(24):10467-80. PubMed ID: 26373723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Scale-Independent Microfluidic Production of Cationic Liposomal Adjuvants and Development of Enhanced Lymphatic Targeting Strategies.
    Roces CB; Khadke S; Christensen D; Perrie Y
    Mol Pharm; 2019 Oct; 16(10):4372-4386. PubMed ID: 31437396
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A strong adjuvant based on glycol-chitosan-coated lipid-polymer hybrid nanoparticles potentiates mucosal immune responses against the recombinant Chlamydia trachomatis fusion antigen CTH522.
    Rose F; Wern JE; Gavins F; Andersen P; Follmann F; Foged C
    J Control Release; 2018 Feb; 271():88-97. PubMed ID: 29217176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Formulation in DDA-MPLA-TDB Liposome Enhances the Immunogenicity and Protective Efficacy of a DNA Vaccine against
    Tian M; Zhou Z; Tan S; Fan X; Li L; Ullah N
    Front Immunol; 2018; 9():310. PubMed ID: 29535714
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potentiation of Th1-Type Immune Responses to
    Ko A; Wui SR; Ryu JI; Lee YJ; Hien DTT; Rhee I; Shin SJ; Park SA; Kim KS; Cho YJ; Lee NG
    J Microbiol Biotechnol; 2018 Jan; 28(1):136-144. PubMed ID: 29081214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.